Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The International Journal of Neuropsychopharmacology|March 29, 2025
Lurasidone response in bipolar type I depression with childhood trauma exposureHernan F Guillen-Burgos, Juan F Galvez-Florez, Sergio Moreno-López, et al.
General Hospital Psychiatry|September 10, 2023
Factors associated with mental health outcomes after COVID-19: A 24-month follow-up longitudinal studyHernan F Guillen-Burgos, Juan Francisco Galvez-Florez, Sergio Moreno-Lopez, et al.
Medical Cannabis and Cannabinoids|October 30, 2024
Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in ColombiaJuan F Galvez-Florez, Hernan F Guillen-Burgos, Camilo A Flórez-Puentes, et al.
Journal of Affective Disorders|June 21, 2026
Investigating the effects of antidepressants on measures of insulin resistance in major depressive disorder: A systematic reviewSabrina Wong, Gia Han Le, Yang Jing Zheng, et al.
The Journal of Clinical Psychiatry|May 8, 2025
Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World EvidenceHernan F Guillen-Burgos, Juan F Galvez-Florez, Sergio Moreno-López, et al.
Brain and Behavior|September 9, 2025
Shared Genetic Architecture Among Severe Mental Disorders: A System Biology Approach Based on Protein-Protein InteractionHernan F Guillen-Burgos, Valentina Vanegas, Isabella Gonzalez, et al.
Psychiatric Research and Clinical Practice|June 23, 2025
Major Depressive Disorder in Long COVID and Exposure to Pro-Inflammatory Cytokines During Infection by SARS-CoV-2Hernan F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-López, et al.
CNS Spectrums|August 12, 2025
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatmentsGia Han Le, Sabrina Wong, Stavroula Bargiota, et al.
Pageof 2